When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. CDC lowers recommendation age for pneumonia vaccine to adults ...

   www.aol.com/cdc-recommends-pneumonia-vaccine...

   Doctors have long urged people ages 50 and older to get a shot to protect against bacterial pneumonia. The Centers for Disease Control and Prevention now agrees.

3. Pneumococcal vaccine - Wikipedia

   en.wikipedia.org/wiki/Pneumococcal_vaccine

   The national vaccination program started including the pneumococcal vaccine for newborns in April 2006. [19] The Health Council advised in 2018 that those who are over the age of 60 should also be vaccinated on a 5-year recurring schedule. The resulting program from this, NPPV, started at the end of 2020. [20]

4. It's Cold & Flu Season: Here's How to Tell if Your Senior ...

   www.aol.com/cold-flu-season-heres-tell-165900863...

   Seniors 65 and over are at an increased risk of death from pneumonia, especially if they have preexisting health problems. If a senior has chronic health conditions, like heart or kidney disease ...

5. WellPoint Urges Seniors to Get Flu, Pneumonia Vaccines - AOL

   www.aol.com/2012/12/28/wellpoint-urges-seniors...

   WellPoint Urges Seniors to Get Flu, Pneumonia Vaccines For older adults, the seasonal flu can be very serious, even deadly INDIANAPOLIS--(BUSINESS WIRE)-- The seasonal flu can be serious for ...

6. Pneumococcal conjugate vaccine - Wikipedia

   en.wikipedia.org/wiki/Pneumococcal_conjugate_vaccine

   Prevnar vaccine. Prevnar 20 (PCV20) is the third version of a vaccine produced by the Wyeth subsidiary of Pfizer.In April 2023, the FDA approved Prevnar 20 for the prevention of invasive disease caused by the 20 different serotypes of S. pneumoniae contained in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) for individuals 6 ...

7. Pneumococcal polysaccharide vaccine - Wikipedia

   en.wikipedia.org/wiki/Pneumococcal...

   The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).